Intrepid Potash heads into its Q1 2026 earnings report today with a clear insider signal and a stock that has sharply underperformed its fertilizer peers.
The most telling data point is insider activity. The CEO, general counsel, and chief accounting officer all sold shares in March — the CEO unloading 3,297 shares at $41.94 on March 17, the general counsel trimming 3,061 shares across two transactions. The chief accounting officer added a further 711-share sale in April at $37.35. Net insider activity over the past 90 days totals roughly $332,000 in sales — a modest sum in absolute terms, but a consistent directional signal from three separate C-suite holders.
That selling has, so far, looked well-timed. IPI has fallen 14% over the past month to $37.67, dropping another 6% on Wednesday alone. The peer group tells a contrasting story. Closely correlated names CF Industries and LXU each gained more than 1.7% and 6.5% respectively on the same session. Nutrien rose nearly 2%. added 1.3%. IPI moved in the opposite direction to every major fertilizer peer on Wednesday — an unusual divergence heading into the print.
Short positioning does not tell an aggressive story. Short interest is just 2.6% of the free float — low enough that bears have not made a meaningful directional bet. Borrow costs have eased sharply, dropping 26% over the week to 0.35%, and borrow availability remains loose. The ORTEX short score of 33 is mid-range and has edged lower from 34.3 two weeks ago, suggesting shorts are not building into the event. Options positioning has shifted modestly more cautious — the put/call ratio is running at 0.34, above its 20-day average of 0.29, though still well below its 52-week high of 0.91. The move is notable but not extreme.
The analyst picture is stale — the only active coverage on record is a UBS Sell rating with a $25 target, last updated in early March. At $37.67, IPI is trading roughly 50% above that target, a gap that warrants treating the figure with caution given the elapsed time and the price divergence. What the print will test is whether IPI's Q1 numbers can justify that premium to the lone analyst's valuation — or whether the insider selling and peer underperformance are signalling something the broader market is only beginning to price in.
See the live data behind this article on ORTEX.
Open IPI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
